217 related articles for article (PubMed ID: 22868365)
21. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with long-term follow-up.
Takeshita T; Tsuda H; Moriya T; Yamasaki T; Asakawa H; Ueda S; Sato K; Aida S; Tamai S; Matsubara O; Hase K; Yamamoto J
Ann Surg Oncol; 2012 Apr; 19(4):1160-6. PubMed ID: 21989659
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
[TBL] [Abstract][Full Text] [Related]
24. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
[TBL] [Abstract][Full Text] [Related]
26. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
27. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
28. Update on the NSABP and ACOSOG breast cancer sentinel node trials.
White RL; Wilke LG
Am Surg; 2004 May; 70(5):420-4. PubMed ID: 15156950
[TBL] [Abstract][Full Text] [Related]
29. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery.
Kittaka N; Tokui R; Ota C; Hashimoto Y; Motomura K; Ishitobi M; Nakayama T; Tamaki Y
Int J Clin Oncol; 2018 Oct; 23(5):860-866. PubMed ID: 29789974
[TBL] [Abstract][Full Text] [Related]
30. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
[TBL] [Abstract][Full Text] [Related]
31. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
32. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
33. Impact of Axillary Dissection Among Patients With Sentinel Node-Positive Breast Cancer Undergoing Mastectomy.
Sun J; Mathias BJ; Laronga C; Sun W; Zhou JM; Fulp WJ; Kiluk JV; Lee MC
J Natl Compr Canc Netw; 2021 Jan; 19(1):40-47. PubMed ID: 33406495
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
35. Sentinel node biopsy in ductal carcinoma in situ patients.
Pendas S; Dauway E; Giuliano R; Ku N; Cox CE; Reintgen DS
Ann Surg Oncol; 2000; 7(1):15-20. PubMed ID: 10674443
[TBL] [Abstract][Full Text] [Related]
36. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients.
Heuts EM; van der Ent FW; Hulsewé KW; Heeren PA; Hoofwijk AG
Acta Chir Belg; 2007 Jun; 107(3):279-83. PubMed ID: 17685253
[TBL] [Abstract][Full Text] [Related]
37. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Boughey JC
Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
[TBL] [Abstract][Full Text] [Related]
38. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
[TBL] [Abstract][Full Text] [Related]
40. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.
Guenther JM; Hansen NM; DiFronzo LA; Giuliano AE; Collins JC; Grube BL; O'Connell TX
Arch Surg; 2003 Jan; 138(1):52-6. PubMed ID: 12511150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
